Liquidia Technologies, Inc.

Contributing Author

Recent Articles by Liquidia Technologies, Inc.

May-23

U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) LQDA GlobeNewswire